Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
9.98
-0.06 (-0.60%)
At close: Dec 15, 2025, 4:00 PM EST
9.98
0.00 (0.00%)
After-hours: Dec 15, 2025, 5:27 PM EST
Immatics Employees
As of December 31, 2024, Immatics had 682 total employees, including 554 full-time and 128 part-time employees. The number of employees increased by 147 or 27.48% compared to the previous year.
Employees
682
Change (1Y)
147
Growth (1Y)
27.48%
Revenue / Employee
$145,814
Profits / Employee
-$206,435
Market Cap
1.21B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 682 | 147 | 27.48% |
| Dec 31, 2023 | 535 | 93 | 21.04% |
| Dec 31, 2022 | 442 | 61 | 16.01% |
| Dec 31, 2021 | 381 | 98 | 34.63% |
| Dec 31, 2020 | 283 | 56 | 24.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMTX News
- 4 days ago - Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress - GlobeNewsWire
- 10 days ago - Immatics Announces $125 Million Underwritten Offering - GlobeNewsWire
- 4 weeks ago - Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps - GlobeNewsWire
- 7 weeks ago - Immatics Appoints Amie Krause as Chief People Officer - GlobeNewsWire
- 2 months ago - Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium - GlobeNewsWire
- 2 months ago - Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 - Seeking Alpha
- 4 months ago - Immatics Announces Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 7 months ago - Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma - GlobeNewsWire